Claudio Maffeis
Overview
Explore the profile of Claudio Maffeis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
238
Citations
2732
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Giorgino F, Bonfanti R, Castaldo F, Irace C, Laurenzi A, Maffeis C, et al.
J Diabetes Sci Technol
. 2025 Feb;
:19322968251316577.
PMID: 39927665
Background: Smart systems for multiple daily injections (Smart MDI) integrate continuous glucose monitoring, connected insulin pens, smartphone apps, and cloud-based data storage to provide bolus and corrective dose suggestions, reminders/alerts,...
2.
Johnson B, Chadwick P, Pryde S, Seidler A, Hunter K, Aberoumand M, et al.
Int J Behav Nutr Phys Act
. 2025 Feb;
22(1):14.
PMID: 39910407
Background: Early childhood obesity prevention interventions that aim to change parent/caregiver practices related to infant (milk) feeding, food provision and parent feeding, movement (including activity, sedentary behaviour) and/or sleep health...
3.
Franceschi R, Pertile R, Marigliano M, Mozzillo E, Maffeis C, Zaffani S, et al.
Diabetes Res Clin Pract
. 2024 Dec;
219():111962.
PMID: 39675483
Aims: New technology has been reported as a factor driving people to choose an automatic insulin delivery system (AIDs) and to sustain its acceptance. We aimed to explore the role...
4.
Maffeis C, Morandi A, Zusi C, Olivieri F, Fornari E, Cavarzere P, et al.
Diabetes Obes Metab
. 2024 Nov;
27(2):825-834.
PMID: 39611214
Aims: Fibroblast growth factor 21 (FGF21) decreases hepatic lipogenesis in animal models, and FGF21 analogues decrease serum triglycerides (TG) in adults in phase-2 trials. On the other hand, serum FGF21...
5.
Valerio G, Di Bonito P, Di Sessa A, Ballarin G, Calcaterra V, Corica D, et al.
Children (Basel)
. 2024 Nov;
11(11).
PMID: 39594920
The pediatric definition of severe obesity (OB) depends on the body mass index (BMI) references. We evaluated different BMI-derived metrics of the World Health Organization (WHO) system to define which...
6.
Di Bonito P, Di Sessa A, Licenziati M, Corica D, Wasniewska M, Del Giudice E, et al.
Rev Cardiovasc Med
. 2024 Nov;
25(10):353.
PMID: 39484121
No abstract available.
7.
Morandi A, Umano G, Vania A, Guglielmi V, Muscogiuri G, Maffeis C, et al.
Eat Weight Disord
. 2024 Oct;
29(1):68.
PMID: 39477859
No abstract available.
8.
Morandi A, Fornari E, Corradi M, Umano G, Olivieri F, Piona C, et al.
Pediatr Obes
. 2024 Oct;
19(12):e13183.
PMID: 39462520
Background: The diagnosis of monogenic obesity is burdened by frequent variants of uncertain significance (VUS). We describe our real-life approach of variant reassessment over time and we assess whether inconclusive...
9.
Valerio G, Di Bonito P, Calcaterra V, Cherubini V, Corica D, de Sanctis L, et al.
Ital J Pediatr
. 2024 Oct;
50(1):205.
PMID: 39380079
Despite the implementation of preventive measures to counteract the obesity epidemics, the prevalence of childhood obesity is still alarming all over the world. Childhood obesity is the most common risk...
10.
Maffeis C, Piona C, Morandi A, Marigliano M, Morotti E, Mancioppi V, et al.
Diabetes Obes Metab
. 2024 Sep;
26(12):5896-5905.
PMID: 39344839
Aim: The aim was to examine the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), a risk factor for atherosclerotic cardiovascular disease, and its association with glycaemic control metrics in...